Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Journal of Basic and Clinical Physiology and Pharmacology

Editor-in-Chief: Horowitz, Michal

Editorial Board: Das, Kusal K. / Epstein, Yoram / S. Gershon MD, Elliot / Kodesh , Einat / Kohen, Ron / Lichtstein, David / Maloyan, Alina / Mechoulam, Raphael / Roth, Joachim / Schneider, Suzanne / Shohami, Esther / Sohmer, Haim / Yoshikawa, Toshikazu / Tam, Joseph

CiteScore 2016: 1.01

SCImago Journal Rank (SJR) 2016: 0.349
Source Normalized Impact per Paper (SNIP) 2016: 0.495

See all formats and pricing
More options …
Volume 29, Issue 1


Indexes of the erythropoietin level in the blood plasma of chronic heart failure patients with anemia

Kamala Kh. Zahidova
  • Corresponding author
  • Department of Cardiology of Azerbaijan State Advanced Training Institute for Doctors named after A. Aliyev, Baku, The Republic of Azerbaijan, Phone: (994) 12 4314033
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2017-12-07 | DOI: https://doi.org/10.1515/jbcpp-2016-0102



Anemia aggravates the disease course and the survival rate of chronic heart failure (CHF) patients. The purpose of the study was to investigate the level of erythropoietin (EPO) in CHF patients with anemic syndrome, with the aim to more accurately assess the severity of the disease and its treatment, depending on the anemia degree.


Patients with ischemic CHF of I–IV functional class (FC) with and without anemia were examined (total number of patients=208, patients with anemia=174). The EPO was determined using the enzyme-linked immunosorbent assay. Before treatment, the patients underwent the following medical therapy: angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, long-acting nitrates, diuretics, digoxin, and beta-blockers at individual doses. Depending on the plasma EPO level, the CHF patients with anemia were divided into four randomized groups in terms of treatment.


Normal erythropoietinemia was found in 36.2% of the CHF patients with anemic syndrome (I–III FC), hypoerythropoietinemia in 44.8% (III–IV FC), and hypererythropoietinemia in 18.96% (III–V FC). The EPO level in the blood plasma of the patients with I–II FC CHF with hypoerythropoietinemia, who were treated with methoxy polyethylene glycol-epoetin β (MEB), increased by 2.2 times. Combination therapy with disease-modifying drugs and MEB led to a significant increase in the plasma EPO level in the CHF patients with hypoerythropoietinemia.


It was shown that the EPO level in patients with CHF and anemia did not always drop. Hypererythropoietinemia in patients with CHF and anemia leads to an unfavorable treatment prediction. This necessitates the investigation of the EPO level in all patients with CHF before and after treatment, with the aim of correcting the anemic syndrome. The research showed that the combined therapy of patients with CHF and anemia using MEB medication and iron with regard to the EPO level in the blood plasma improved their overall physical condition, reduced heart failure symptoms and hospitalization frequency, and demonstrated a clear tendency to reduce the general mortality rate.

Keywords: anemia; chronic heart failure; erythropoietin; ferritin; intravenous iron; methoxy polyethylene glycol-epoetin β; NTproBNP


  • 1.

    Go AS, Yang J, Ackerson LM, Lepper K, Robbins S, Massie BM, et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the anemia in chronic heart failure: outcomes and resource utilization (ANCHOR) study. Circulation 2006;113:2713–23.CrossrefPubMedGoogle Scholar

  • 2.

    Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, et al. Anemia and mortality in heart failure patients: a systematic review and meta-analysis. J Am Coll Cardiol 2008;52:818–27.CrossrefWeb of SciencePubMedGoogle Scholar

  • 3.

    Anand IS. Anemia and chronic heart failure. Implications and treatment options. J Am Coll Cardiol 2008;52:501–11.Web of ScienceCrossrefPubMedGoogle Scholar

  • 4.

    Tang Y-D, Katz SD. Anemia in chronic heart failure. Prevalence, etiology, clinical correlates, and treatment options. Circulation 2006;113:2454–61.PubMedCrossrefGoogle Scholar

  • 5.

    van der Meer P, Lok DJ, Januzzi JL, Lipsic E, van Wijngaarden J, Voors AA, et al. Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients. Europ Heart J 2008;29:1510–5.CrossrefGoogle Scholar

  • 6.

    Stamosa TD, Silver MA. Management of anemia in heart failure. Curr Opin Cardiol 2010;25:148–54.Web of ScienceCrossrefPubMedGoogle Scholar

  • 7.

    Moe GW, Ezekowitz JA, O’Meara E, Lepage S, Howlett JG, Fremes S, et al. The 2014 Canadian cardiovascular society heart failure management guidelines focus update: anemia, biomarkers, and recent therapeutic trial implications. Can J Cardiol 2015;31:3–16.Web of ScienceCrossrefGoogle Scholar

  • 8.

    Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12,065 patients with new-onset heart failure. Circulation 2003;107:223–5.PubMedCrossrefGoogle Scholar

  • 9.

    Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002;40:1414–21.CrossrefPubMedGoogle Scholar

  • 10.

    Gao E, Koch WJ. Is erythropoietin behind maladaptive anemic heart failure? Am J Physiol Heart Circ Physiol 2009;296:H559–60.CrossrefPubMedGoogle Scholar

  • 11.

    Kallergis EM, Mavrakis HE, Vardas PE. Anaemia and heart failure: is its correction a therapeutic target? The role of erythropoietin. Hell J Cardiol 2005;46:222–5.Google Scholar

  • 12.

    Smith KJ, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects of erythropoietin. Cardiovasc Res 2003;59:538–48.PubMedCrossrefGoogle Scholar

  • 13.

    van der Meera P, Voorsa AA, Lipsica E, van Gilstb WH, van Veldhuisen DJ. Erythropoietin in cardiovascular diseases. Europ Heart J 2004;25:285–91.CrossrefGoogle Scholar

  • 14.

    Palazzuoli A, Silverberg D, Iovine F, Capobianco S, Giannotti G, Calabrò A. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J 2006;152:1096–115.PubMedGoogle Scholar

  • 15.

    George J, Patal S, Wexler D, Abashidze A, Shmilovich H, Barak T, et al. Circulating erythropoietin levels and prognosis in patients with congestive heart failure. Comparison with neurohormonal and inflammatory markers. Arch Intern Med 2005;165:1304–09.PubMedCrossrefGoogle Scholar

  • 16.

    Androne AS, Katz SD, Lund L, LaManca J, Hudaihed A, Hryniewicz K, et al. Hemodilution is common in patients with advanced heart failure. Circulation 2003;107:226–9.CrossrefPubMedGoogle Scholar

  • 17.

    Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000;35:1737–44.CrossrefGoogle Scholar

  • 18.

    Pham I, Andrivet P, Sediame S, Defouilloy C, Moutereau S, Wirquin V, et al. Increased erythropoietin synthesis in patients with COLD or left heart failure is related to alterations in renal haemodynamics. Eur J Clin Invest 2001;31:103–9.PubMedCrossrefGoogle Scholar

  • 19.

    Silverberg D, Waxler D, Blum M, Wollman Y. The interaction between heart failure, renal failure and anemia – the cardio-renal anemia syndrome. Blood Purify 2004;22:277–84.CrossrefGoogle Scholar

  • 20.

    Zahidova KK. The role of the level of serum erythropoietin on the patients with anemic heart failure. Eur J Heart Fail (Supplements) 2013;12(S1):71.Google Scholar

  • 21.

    Silverberg DS, Wexler D, Iaina A. The importance of anemia and its correction in the management of severe congestive heart failure. Eur J Heart Fail 2002;4:681–6.CrossrefPubMedGoogle Scholar

  • 22.

    Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001;37:1775–80.CrossrefGoogle Scholar

  • 23.

    van Veldhuisen DJ, McMurray JJ. Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial. Eur J Heart Fail 2007;9:110–2.PubMedCrossrefWeb of ScienceGoogle Scholar

About the article

Received: 2016-07-04

Accepted: 2017-09-19

Published Online: 2017-12-07

Published in Print: 2018-01-26

Author contributions: The author has accepted responsibility for the entire content of this submitted manuscript and approved the submission.

Research funding: None declared.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of the data; in the writing of the report; or in the decision to submit the report for publication.

Citation Information: Journal of Basic and Clinical Physiology and Pharmacology, Volume 29, Issue 1, Pages 11–17, ISSN (Online) 2191-0286, ISSN (Print) 0792-6855, DOI: https://doi.org/10.1515/jbcpp-2016-0102.

Export Citation

©2018 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

N. T. Vatutin, G. G. Taradin, I. V. Kanisheva, and V. V. Venzheha
Kardiologiia, 2019, Volume 59, Number 4S, Page 4
Damiano Magrì, Fabiana De Martino, Federica Moscucci, Piergiuseppe Agostoni, and Susanna Sciomer
Heart Failure Clinics, 2019, Volume 15, Number 3, Page 359

Comments (0)

Please log in or register to comment.
Log in